STRI has been all about turning the future into a reality that bears greater meaning for all mankind
Now we stand at a critical turning point where our simple but meaningful discovery is turning into a tangible discovery thanks to the many collaborators who are looking forward together with us.
2010 - Present
2010 - Present
2023
STRI published the research article :
1. Recovery from BEll's palsy after treatment using uncultured umbilical cord-derived mesenchymal stem cells: A case report". World J Clin Cases. 2023 April 26;11(12):2817-2824. DOI : 10.12998/wjcc.v11.i12.2817
2022
Approval Cell Facility Lisencse from Japan FDA
STRI published the research article :
1. Treatment of syringomyelia using uncultured umbilical cord mesenchymal stem cells: A case report and review of literature
World J Stem Cells. 2022 April 26; 14(4): 303-309. DOI: 10.4252/wjsc.v14.i4.303
2021
Approval Cell Facility License from KFDA
Approval Human Cell-Related Operation License from KFDA
STRI published the research articles :
1. "Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: A case report". World J Stem Cells. 2021 Aug 26;13(8):1151-1159. doi: 10.4252/wjsc.v13.i8.1151.
2. "Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report". World J Clin Cases. 2021 Aug 16;9(23):6798-6803. doi: 10.12998/wjcc.v9.i23.6798.
3. "Alopecia treatment using minimally manipulated human umbilical cord-derived mesenchymal stem cells: Three case reports and review of literature". World J Clin Cases 2021; 9(15): 3741-3751 [PMID: 34046478 DOI: 10.12998/wjcc.v9.i15.3741].
2020
STRI has applied 334 patents related to nEPS over 156 countries and 283 patents are registered in the US, the EU, Israel, Singapore, Australia, Japan, Russia, China, etc.
2018
Registered 280 newly Elicited pluripotent stem cells without side effects (nEPS) patents in Korea,US, EU, Australia, Singapore, Japan and Isreal etc.
Research collaboration with University of Michigan
2016
Pre-clinical trialusing hepatocyte-like differentiated cells from nEPS (from Korea) with Seoul National Univ. Bundang Hospital
2015
Registered newly Elicited Pluripotent Stem Cells without side effects (nEPS) 16 registered and 94 related patents applied in 146 countries
2014
Differentiated nEPS cells into six different organ cells – pancreatic beta cells, neurocytes, hepatocytes, adipocytes, osteoblasts and chondrocytes
2013
Discovered the world’s first newly Elicited Pluripotent Stem Cells without side effects (nEPS)
1989 - 2009
1989 - 2009
2007
Research arm expanded into the Stem Cell Treatment & Research Institute
2000
STRI Fundamental Sciences Department launched with 3 sub-divisions
STRI Life Sciences Research Center receives Korea Industrial Technology Association (KOITA) certification
STRI Agricultural Life Sciences Research Center completed Plant Products Manufacturing Plant
1999
Renamed STRI Stem Cell Research Institute
1997
STC Nara opens manufacturing plant in Cheonan
Established STC Agricultural Life Sciences Research Center
Established STRI Life Sciences Research Center (with the core values of Soul, Treatment & Cell to contribute to mankind by developing stem cell based therapy with a righteous mind.)
